DrugDashboards

Quinapril and Hydrochlorothiazide

Quinapril and Hydrochlorothiazide · QUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 · Tablet · Oral · Chartwell RX, LLC

NDC 62135-0669-90 · 90 TABLET in 1 BOTTLE · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. It is in shortage right now. One of its named manufacturing plants, Chartwell Pharmaceuticals Congers, LLC., failed FDA inspectionwithin the last two years — the agency’s most serious outcome.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Part D point of sale (median)$1.18per unitnegotiated price across 4,501 plans — before rebates · Apr 1, 2026
  • Federal contracts pay (FSS)$4.90per unitChartwell RX LLC · Aug 15, 2024

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$1.18per unit
middle half $0.3930$3.92 · 4,501 plans · Apr 1, 2026
Est. net of rebates
≈ $1.18
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
82%of plans cover it
tier 1 · prior auth 0% · step therapy 0% · qty limit 9%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 6 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$441.00
Reported to Texas DSHS · 2026 annual filing · Chartwell RX, LLC

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA076374
TE code
AB
Approval date
Mar 31, 2004
Patents / exclusivity
None on file

Shortage history

  • In shortage now Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)Jan 19, 2023
    month 44 — 3× the typical 14-month oral solid shortage · model puts 23% odds it resolves within 6 months
  • In shortage now Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)Jan 19, 2023
    month 44 — 3× the typical 14-month oral solid shortage · model puts 23% odds it resolves within 6 months
  • In shortage now Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)Jan 19, 2023
    month 44 — 3× the typical 14-month oral solid shortage · model puts 23% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Quinapril and Hydrochlorothiazide (Tablet)

LabelerStrengthFirst seenLast seen
Chartwell RX, LLCQUINAPRIL HYDROCHLORIDE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1Aug 26, 2026Sep 2, 2026
Chartwell RX, LLCQUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1Aug 26, 2026Sep 2, 2026
Chartwell RX, LLCQUINAPRIL HYDROCHLORIDE 20 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1Aug 26, 2026Sep 2, 2026
Chartwell RX, LLCQUINAPRIL HYDROCHLORIDE 25 mg/1; HYDROCHLOROTHIAZIDE 20 mg/1Jul 22, 2026Aug 19, 2026
Chartwell RX, LLCQUINAPRIL HYDROCHLORIDE 12.5 mg/1; HYDROCHLOROTHIAZIDE 10 mg/1Jul 22, 2026Aug 19, 2026
Chartwell RX, LLCQUINAPRIL HYDROCHLORIDE 12.5 mg/1; HYDROCHLOROTHIAZIDE 20 mg/1Jul 22, 2026Aug 19, 2026
Chartwell RX, LLCHYDROCHLOROTHIAZIDE 25 mg/1; QUINAPRIL HYDROCHLORIDE 20 mg/1Jul 15, 2026Jul 15, 2026
Chartwell RX, LLCHYDROCHLOROTHIAZIDE 12.5 mg/1; QUINAPRIL HYDROCHLORIDE 20 mg/1Jul 15, 2026Jul 15, 2026
Chartwell RX, LLCHYDROCHLOROTHIAZIDE 12.5 mg/1; QUINAPRIL HYDROCHLORIDE 10 mg/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Quinapril and Hydrochlorothiazide — NDC 62135-0669-90," retrieved September 3, 2026, https://drugdashboards.com/drug/62135066990.

Free to cite with attribution — see how the data is put together.